The Union Department of Pharmaceuticals finalized a comprehensive policy framework to cap trade margins on patented and specialty oncology medications at thirty percent over the distributor procurement price. The regulatory intervention, drafted in consultation with the National Pharmaceutical Pricing Authority, is projected to slash the maximum retail prices of lifesaving cancer therapies by up to seventy percent across hospitals and pharmacies.
Under the trade margin rationalization formula, pharmaceutical manufacturers and multinational patentees will be prohibited from inflating markups between the landed import cost and retail pharmacy price points. The policy encompasses widely prescribed targeted immunotherapy drugs, monoclonal antibodies, and kinase inhibitors utilized in treating lung, breast, and hematological malignancies.
Oncologists and patient welfare organizations welcomed the move, pointing out that exorbitant cancer therapy expenses frequently push affected families into catastrophic debt and treatment abandonment. Pharmaceutical industry bodies requested transitional periods to align existing wholesale supply contracts, while affirming support for expanding affordable treatment access across India.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://indianexpress.com/article/education/today-news-headlines-for-school-assembly-october-9-2026-anne-carson-wins-nobel-prize-in-literature-for-2026-10912055/